Idrabiotaparinux Sodium
drugOn this page
Also known as Idrabiotaparinux sodicoIdrabiotaparinux sodiqueSsr-126517 sodiumSsr126517 sodium
Summary
Idrabiotaparinux Sodium (CHEMBL4297768) is a phase-3 clinical-stage oligosaccharide; indicated across 3 conditions including atrial fibrillation and thrombotic disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Oligosaccharide
- Indications: 3 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297768 |
| Name | Idrabiotaparinux Sodium |
| Type | Oligosaccharide |
| Max phase | 3 |
Also known as: Idrabiotaparinux sodico, Idrabiotaparinux sodique, Idrabiotaparinux sodium, Ssr-126517 sodium, Ssr126517 sodium, IDRABIOTAPARINUX SODIUM
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| atrial fibrillation | 3 | MONDO:0004981 | EFO:0000275 |
| thrombotic disease | 3 | MONDO:0000831 | MONDO:0000831 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00311090 | PHASE3 | COMPLETED | Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs |
| NCT00345618 | PHASE3 | COMPLETED | Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach |
| NCT00580216 | PHASE3 | TERMINATED | Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: atrial fibrillation, thrombotic disease